FDA nominee sidesteps questions on abortion pill, agency layoffs and other issues

Trump nominee to head up FDA won’t make any commitments on abortion pill access • Wisconsin Examiner

Makaray says he will review data on mifepristone and follow the research where it leads him, with no preconceived ideas about the outcome.

FDA Nominee Makary Calls for ‘More Humility in the Medical Establishment’

In his confirmation hearing to be commissioner of the Food and Drug Administration, Dr. Martin Makary on Thursday decried the hubris of the medical establishment that he said was leading to a distrust of medical professionals by the American public.  “We need more humility in the medical establishment,” Makary told the Senate Committee on Health, Education, Labor, and Pensions, which also heard the testimony of Trump’s nominee to lead the Nation…

5 Takeaways From FDA Nominee Marty Makary’s Hearing - The Thinking Conservative

Dr. Marty Makary, nominee to lead FDA, appeared before the Senate Health, Education, Labor, and Pensions Committee at a confirmation hearing on March 6. The post 5 Takeaways From FDA Nominee Marty Makary’s Hearing appeared first on The Thinking Conservative.

Marty Makary, Often Wrong as Pandemic Critic, Is Poised To Lead the FDA He Railed Against

Panelists at a covid conference last fall were asked to voice their regrets — policies they had supported during the pandemic but had come to see as misguided. Covid contact tracing, one said. Closing schools, another said. Vaccine mandates, a third said. When Marty Makary’s turn came, the Johns Hopkins University surgeon said, “I can’t think of anything,” adding, “The entire covid policy of three to four years felt like a horror movie I was for…

How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?

With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.

FDA nominee evades abortion pill questions

President Donald Trump's pick to lead the Food and Drug Administration largely sidestepped questions Thursday from senators about how he would handle numerous pressing issues before the agency, including recent layoffs, a canceled vaccine meeting and the continued availability of…